- Home
- CLM vs CERT Comparison
CLM vs CERT Comparison
Compare CLM & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLM
- CERT
- Stock Information
- Founded
- CLM 1987
- CERT 2008
- Country
- CLM United States
- CERT United States
- Employees
- CLM N/A
- CERT N/A
- Industry
- CLM Finance/Investors Services
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- CLM Finance
- CERT Technology
- Exchange
- CLM Nasdaq
- CERT Nasdaq
- Market Cap
- CLM 2.1B
- CERT 1.9B
- IPO Year
- CLM N/A
- CERT 2020
- Fundamental
- Price
- CLM $8.43
- CERT $10.71
- Analyst Decision
- CLM
- CERT Buy
- Analyst Count
- CLM 0
- CERT 7
- Target Price
- CLM N/A
- CERT $15.92
- AVG Volume (30 Days)
- CLM 1.4M
- CERT 1.5M
- Earning Date
- CLM 01-01-0001
- CERT 11-06-2024
- Dividend Yield
- CLM 18.74%
- CERT N/A
- EPS Growth
- CLM N/A
- CERT N/A
- EPS
- CLM N/A
- CERT N/A
- Revenue
- CLM N/A
- CERT $372,797,000.00
- Revenue This Year
- CLM N/A
- CERT $10.20
- Revenue Next Year
- CLM N/A
- CERT $10.01
- P/E Ratio
- CLM N/A
- CERT N/A
- Revenue Growth
- CLM N/A
- CERT 5.62
- 52 Week Low
- CLM $6.25
- CERT $9.41
- 52 Week High
- CLM $8.84
- CERT $19.87
- Technical
- Relative Strength Index (RSI)
- CLM 45.19
- CERT 45.72
- Support Level
- CLM $8.16
- CERT $10.31
- Resistance Level
- CLM $8.80
- CERT $11.77
- Average True Range (ATR)
- CLM 0.25
- CERT 0.58
- MACD
- CLM -0.09
- CERT -0.07
- Stochastic Oscillator
- CLM 35.52
- CERT 26.32
About CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.